evidence: Recent advances in immunotherapy and vaccine development for peanut allergy - PMID: 26288733 - PMCID: PMC4530404 - DOI: 10.1177/2051013615591739 [...] Peanut allergy is a common problem and can be the cause of severe, life-threatening allergic reactions. It rarely resolves, with the majority of patients carrying the disease onto adulthood. Peanut allergy poses a significant burden on the quality of life of sufferers and their families, which results mainly from the fear of accidental peanut ingestion, but is also due to dietary and social restrictions. Current standard management involves avoidance, patient education and provision of emergency medication, for use in allergic reactions, when they occur. Efforts have been made to develop a vaccine for peanut allergy. Recent developments have also highlighted the use of immunotherapy, which has shown promise as an active form of treatment and may present a disease-modifying therapy for peanut allergy. So far, results, especially from oral immunotherapy studies, have shown good efficacy in achieving desensitization to peanut with a good safety profile. However, the capacity to induce long-term tolerance has not been demonstrated conclusively yet and larger, phase III studies are required to further investigate safety and efficacy of this intervention. Peanut immunotherapy is not currently recommended for routine clinical use or outside specialist allergy units. [...] Oral Immunotherapy for Peanut Allergy.Annu Rev Med. 2016;67:375-85. doi: 10.1146/annurev-med-061014-094943. Epub 2015 Aug 26. Annu Rev Med. 2016. PMID: 26332004 Review.